investorials.com Soligenix — ticker symbol SNGX — is a biopharmaceutical company focused on treating serious gastrointestinal disease, cancer supportive care, and biodefense vaccines. Of its eight clinical programs in its pipeline targeting $200 million dollar plus orphan markets, four are ready for Phase II clinical trials including SGX203 for pediatric Crohn's disease and SGX942 for oral mucositis in head and neck cancer.. And unlike most biotech companies, NIH and FDA grants have resulted in very little shareholder dilution and a healthy balance sheet, with significant potential upside. For more information, check out their Investorial at investorials.com/companies/sngx

Based on data from the CDC, mayoclinic, pubmed, NIH and cancer.org information on Cervical Cancer